Two new trials registered: TAVI closure device study and aldosterone signaling review
ClinicalTrials.gov listed a randomized TAVI vascular-closure trial and a non-randomized hypertension-aldosterone review study, both not yet recruiting as of early August 2026.
Two studies entered the ClinicalTrials.gov registry during the week of August 4-6, 2026, and neither has begun recruiting.
- SEAL-TAVI (NCT07743697), sponsored by University Hospital, Basel, Switzerland with collaborators including University Hospital Zürich and University Heart Center Freiburg - Bad Krozingen, is designed to test whether a single-suture closure strategy compares to a hybrid closure strategy (one suture plus one plug-based device) to see if using a single suture reduces vessel-related complications and improves patient safety after TAVI1. The randomized, phase not applicable trial was first posted August 4, 2026, is not yet recruiting, and plans to enroll 705 participants1 with primary completion estimated for September 2028.
- DETAIL (NCT07748975), sponsored by DejthidaNathaphong, is a literature synthesis and biospecimen study seeking to identify and analyze the epigenetic, phenotypic, protein variation, metabolites of CYP450 Family 11 Subfamily B, both 1 and 2, human-associated aldosterone protein release, and signaling inhibitory pathways post-aldosterone-mineralocorticoid interaction2 in hypertension patients. The non-randomized, screening-purpose study was first posted August 6, 2026, is not yet recruiting, and lists Enrollment: 100 participants (estimated)2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.